Targeting MTHFD2 to Exploit Cancer-Specific Metabolism and the DNA Damage Response.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37922465.
- Also identified by DOI 10.1158/0008-5472.CAN-23-1290.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The one-carbon folate enzyme methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2 (MTHFD2) is a promising therapeutic target in cancer. MTHFD2 is upregulated across numerous cancer types, promotes growth and metastasis of cancer, and correlates with poorer survival. Recent studies have developed small-molecule inhibitors to the isozymes MTHFD2 and MTHFD1 that show promise as anticancer agents through different mechanisms. This review discusses the current understanding of the function of MTHFD2 in cancer and the status of inhibitors for treating MTHFD2-overexpressing cancers.
Medical subject headings
- Neoplasms
- Antineoplastic Agents